HOXD‐AS2‐STAT3 feedback loop attenuates sensitivity to temozolomide in glioblastoma
CNS Neuroscience & Therapeutics · 2023
DOI: 10.1111/cns.14277 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2023. Verfasst von Zuo-Xin Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, MicroRNAs. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims
Glioblastoma multiforme (GBM) is the deadliest glioma and its resistance to temozolomide (TMZ) remains intractable. Long non‐coding RNAs (lncRNAs) play crucial roles in that and this study aimed to investigate underlying mechanism of HOXD‐AS2‐affected temozolomide sensitivity in glioblastoma.
Methods
We analyzed and validated the aberrant HOXD‐AS2 expression in glioma specimens. Then we explored the function of HOXD‐AS2 in vivo and in vitro and a clinical case was also reviewed to examine our findings. We further performed mechanistic experiments to investigate the mechanism of HOXD‐AS2 in regulating TMZ sensitivity.
Results
Elevated HOXD‐AS2 expression promoted progression and negatively correlated with prognosis of glioma; HOXD‐AS2 attenuated temozolomide sensitivity in vitro and in vivo; The clinical case also showed that lower HOXD‐AS2 sensitized glioblastoma to temozolomide; STAT3‐induced HOXD‐AS2 could interact with IGF2BP2 protein to form a complex and sequentially upregulate STAT3 signaling, thus forming a positive feedback loop regulating TMZ sensitivity in glioblastoma.
Conclusion
Our study elucidated the crucial role of the HOXD‐AS2‐STAT3 positive feedback loop in regulating TMZ sensitivity, suggesting that this could be provided as a potential therapeutic candidate of glioblastoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
- School of Medicine, Chongqing University, Chongqing, China.
- Department of Neurosurgery, Changhai Hospital, Second Military Medical University, Shanghai, China.
ORCID-Profile: Zuo-Xin Zhang, Peng Ren, Guo-Hao Huang, Shuo Zhou, Wei Yang, Lin Yang, Guo-Long Liu, Sheng-Qing Lv
Zitieren
APA
Zhang, Z. X., Ren, P., Cao, Y. Y., Wang, T. T., Huang, G. H., Li, Y., Zhou, S., Yang, W., Yang, L., Liu, G. L., Xiang, Y., Pei, Y. C., Chen, Q. Z., Chen, J. X., & Lv, S. Q. (2023). HOXD‐AS2‐STAT3 feedback loop attenuates sensitivity to temozolomide in glioblastoma. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14277
Vancouver
Zhang ZX, Ren P, Cao YY, Wang TT, Huang GH, Li Y, et al. HOXD‐AS2‐STAT3 feedback loop attenuates sensitivity to temozolomide in glioblastoma. CNS Neuroscience & Therapeutics. 2023. doi:10.1111/cns.14277
BibTeX
@article{Zhang2023,
author = {Zhang, Zuo-Xin and Ren, Peng and Cao, Yong-Yong and Wang, Ting-Ting and Huang, Guo-Hao and Li, Yao and Zhou, Shuo and Yang, Wei and Yang, Lin and Liu, Guo-Long and Xiang, Yan and Pei, Yu-Chun and Chen, Qiu-Zi and Chen, Ju-Xiang and Lv, Sheng-Qing},
title = {HOXD‐AS2‐STAT3 feedback loop attenuates sensitivity to temozolomide in glioblastoma},
journal = {CNS Neuroscience & Therapeutics},
year = {2023},
doi = {10.1111/cns.14277}
}
EUVIMED